|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date27 Jul 2020 |
A Randomized, Open Label, Two Stage, Multicentre, Parallel Group, Multiple Dose, Steady State Study to Compare Bioavailability and Characterize Pharmacokinetic Profile of Test Formulation[Paliperidone Palmitate Extended Release Injectable Suspension By Accord Healthcare,Administered Every Three Months] Relative to Reference Formulation [Invega Trinza®(Paliperidone Palmitate Extended Release Injectable Suspension) By Janssen Pharmaceuticals]and to Establish Bioequivalence in Patients with Schizophrenia Already Receiving A Stable Regimen of Paliperidone Palmitate Extended Release Injectable Suspension.
100 Clinical Results associated with Accord Healthcare, Inc. (Canada)
0 Patents (Medical) associated with Accord Healthcare, Inc. (Canada)
100 Deals associated with Accord Healthcare, Inc. (Canada)
100 Translational Medicine associated with Accord Healthcare, Inc. (Canada)